Stockscreener 앱 받기
0.55
1.81%
0.0098
시간 외 거래:
.55
전일 마감가:
$0.5402
열려 있는:
$0.54
하루 거래량:
41,223
Relative Volume:
0.23
시가총액:
$2.59M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+10.00%
1개월 성능:
-11.29%
6개월 성능:
-15.37%
1년 성능:
+0.00%
1일 변동 폭
$0.52
$0.5899
1주일 범위
$0.4802
$0.625
52주 변동 폭
$0.185
$3.00
Entero Therapeutics Inc Stock (ENTO) Company Profile
명칭
Entero Therapeutics Inc
전화
561-589-7020
주소
777 YAMATO ROAD, BOCA RATON
ENTO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENTO
Entero Therapeutics Inc
|
0.55 | 2.59M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.68 | 125.39B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
717.50 | 79.10B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
671.39 | 40.58B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.31 | 35.43B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.56 | 29.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Entero Therapeutics Inc 주식(ENTO)의 최신 뉴스
AzurRx BioPharma Announces Results of Phase IIa Trial of MS1819-SD in Exocrine Pancreatic Insufficiency - Marketscreener.com
Entero Therapeutics faces Nasdaq delisting over meeting lapse By Investing.com - Investing.com Australia
Entero Therapeutics faces Nasdaq delisting over meeting lapse - Investing.com
Entero therapeutics CFO sells $465 in stock - Investing.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SUM, STAF, ALVR, ENTO on Behalf of Shareholders - The Malaysian Reserve
$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of SUM, ENTO, ALVR and STAF - GlobeNewswire Inc.
ENTO (Entero Therapeutics) Price-to-Operating-Cash-Flow : (As of Dec. 04, 2024) - GuruFocus.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
First Wave BioPharma, Inc. announced that it expects to receive $4 million in funding - Marketscreener.com
Deal Watch: Sarepta Targets RNAi In Broad Collaboration With Arrowhead - News & Insights
Entero Therapeutics faces financial obligations acceleration By Investing.com - Investing.com Nigeria
Entero Therapeutics faces financial obligations acceleration - Investing.com India
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STAF, ATSG, ENTO, AVTE on Behalf of Shareholders - Marketscreener.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CDE, ALVR, PULM, ENTO on Behalf of Shareholders - The Malaysian Reserve
Finansavisen - Finansavisen
Celiac Disease Pipeline Grows as 25+ Key Pharma Companies Join the Fight for Innovative Treatments | DelveInsight - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates - GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders - AccessWire
ENTERO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Entero Therapeutics, Inc.ENTO - Marketscreener.com
Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum - The Manila Times
Entero Therapeutics announces proposed reverse merger with Journey Therapeutics - TipRanks
Entero finds lifeline in reverse merger with nano-immunoconjugate firm Journey - FirstWord Pharma
Ademi LLP Investigates Whether Entero Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders - Business Wire
Shareholder Alert: Ademi LLP Investigates Whether Entero Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders - The Bakersfield Californian
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AE, LBRDA, PULM, ENTO on Behalf of Shareholders - The Malaysian Reserve
ENTO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Entero Therapeutics, Inc. Is Fair to Shareholders - Business Wire
Entero, Journey to merge, creating oncology-focused biopharma By Investing.com - Investing.com Canada
Journey Therapeutics, Inc. entered into a binding term sheet to acquire Entero Therapeutics, Inc. in a reverse merger transaction. - Marketscreener.com
Entero stock in focus amid reverse merger plans (ENTO:NASDAQ) - Seeking Alpha
Entero, Journey to merge, creating oncology-focused biopharma - Investing.com
Entero Therapeutics Announces Proposed Reverse Merger with - GlobeNewswire
Entero Therapeutics Announces 99% Reverse Merger Deal with Journey's Cancer Platform | ENTO Stock News - StockTitan
FIRST WAVE BIOPHARMA, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
AzurRx BioPharma, Inc. Adds Two New Clinical Trial Sites in Europe for Phase 2b OPTION 2 Extension Study of MS1819 Immediate-Release Capsules in Cystic Fibrosis Patients - Marketscreener.com
AzurRx BioPharma Announces First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in Cystic Fibrosis Patients - Marketscreener.com
Layoff Tracker: Marinus Cuts Employees After Disappointing Phase III Trial - BioSpace
How Are Things Looking For Entero Therapeutics Inc. (NASDAQ: ENTO) For The Short Term? - Stocks Register
Entero therapeutics CFO sells shares to cover tax obligations By Investing.com - Investing.com South Africa
Entero therapeutics CFO sells shares to cover tax obligations - Investing.com India
Entero Therapeutics Inc.’s Market Journey: Closing Weak at 0.42, Down -19.41 - The Dwinnex
Taking on analysts’ expectations and winning: Entero Therapeutics Inc. (ENTO) - SETE News
Potential Price Increase for Entero Therapeutics Inc. (ENTO) After Recent Insider Activity - Knox Daily
Market cap of Entero Therapeutics Inc. [ENTO] reaches 1.95M – now what? - The DBT News
Entero Therapeutics Inc (ENTO) 재무 분석
Entero Therapeutics Inc (ENTO)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.54%
자본화:
|
볼륨(24시간):